Growing Concern over the Efficacy of Vancomycin is Prompting Greater Use of Branded Therapies for the Treatment of MRSA Infections

July 7, 2014

To Effectively Compete with Current Anti-MRSA Therapies, Emerging Agents Will Need to be Amenable to Outpatient Use, According to Findings from Decision Resources Group

BURLINGTON, Mass., July 7, 2014 /PRNewswire/ — Decision Resources Group finds that, although vancomycin continues to be the standard-of-care for infections caused by methicillin-resistant Staphylococcus aureus (MRSA), there is growing concern among infectious disease (ID) specialists over rising vancomycin minimum inhibitory concentrations (MICs) among hospital MRSA isolates. Nearly two-thirds of ID specialists who have made changes to their prescribing practices over the past two years indicated using higher dosages of vancomycin, or “push the dose”, in order to increase trough levels of the drug. At the same time, among physicians who indicated increasing usage of Cubist’s Cubicin, Pfizer’s Zyvox, or Forest’s Teflaro in the last 12 months, elevated vancomycin MICs were cited as one of the most common reasons for greater prescribing of these brands.


Other key findings from the TreatmentTrends report entitled Methicillin-Resistant Staphylococcus Aureus 2014 (US):

    --  Hospital-acquired (HA) MRSA and community-acquired (CA) MRSA: HA-MRSA
        and CA-MRSA remain the two most concerning Gram-positive pathogens among
        surveyed ID specialists. In general, MRSA patients incur greater costs
        per day and longer hospital stays compared to patients with infections
        due to other Gram-positive pathogens. In addition, MRSA infections are
        more likely to require later lines of therapy and/or use of combination
    --  Outpatient parenteral antibiotic therapy (OPAT): More than half of
        surveyed physicians indicated that over the past two years they have
        increased the number of MRSA patients discharged on OPAT. As this trend
        continues, new parenteral agents with convenient dosing schemes such as
        Dalvance's (Durata) two dose regimen administered weekly and Orbactiv's
        (The Medicines Company) single dose regimen will be well-positioned to
        compete in this highly competitive market. Dalvance is expected to be
        the first to launch, having received FDA approval for treatment of
        cSSSIs/ABSSSIs in May 2014. Orbactiv's NDA is currently under FDA review
        with a PDUFA date scheduled for August 6, 2014.

Comments from Decision Resources Group Analyst Maria Ascano, Ph.D.:

    --  "As hospitals aim to reduce healthcare costs by minimizing hospital
        admissions or the length of hospital stays, agents amenable to
        outpatient use, such as having convenient dosing for OPAT or
        availability in bioequivalent oral formulations, will allow physicians
        to discharge MRSA patients earlier. However, as pressure mounts for
        hospitals to reduce readmissions rates, it will be critical for these
        outpatient therapies to demonstrate high clinical cure rates."
    --  "Three-quarters of surveyed ID specialists indicated they would
        prescribe Cubist's second-generation oxazolidinone, Sivextro, over
        Pfizer's Zyvox for the treatment of skin infections due to MRSA. These
        results highlight high physician awareness of Sivextro's key
        improvements over Zyvox, including less-frequent dosing, similar
        efficacy in a shorter course of therapy, and potential for fewer adverse
        events--particularly those associated with prolonged use."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

For more information, contact:

Decision Resources Group

Christopher Comfort



SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus